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Abstract
Background: Fluticasone furoate (FF)/vilanterol (VI) is a once daily (OD) inhaled corticosteroid/long-acting β2-agonist
combination asthma therapy approved in Japan and the EU. FF/VI efficacy and safety data from asthma studies
including patients in East Asia were evaluated to assess ethnic sensitivity.
Methods: Randomized, double-blind, multicenter Phase IIb/III trials were assessed. Change from baseline relative
to placebo or twice-daily fluticasone propionate 500 μg in trough FEV1 was compared between patients from
Japan (N = 148) and Not-Japan (N = 3,066; three studies). Adverse events (AEs), laboratory results, and electrocardiograms
were compared between patients from Japan + Korea (N = 188) and Not-Japan + Korea (N = 3,840; five studies).
Results: For trough FEV1, improvements from baseline (least-squares mean difference [95 % confidence interval])
were reported for FF/VI 100/25 μg OD versus placebo at Week 12 (Japan: 0.323 L [0.104–0.542]; Not-Japan:
0.168 L [0.095–0.241]). Improvements from baseline (least-squares mean change [standard error]) were reported with
FF/VI 200/25 μg OD at Week 24 (Japan: 0.355 L [0.1152]; Not-Japan: 0.396 L [0.0313]). A greater proportion of patients
from Japan + Korea versus Not-Japan + Korea reported AEs in all treatment arms including placebo (FF/VI 100/25 μg:
79 % versus 57 %; FF/VI 200/25 μg: 64 % versus 45 %; placebo: 41 % versus 23 %). There were no notable differences
in treatment-related or class-related AEs. No clinically significant changes in electrocardiogram assessments or
statistically significant differences in 24 h urinary cortisol excretion were observed between the Japan + Korea
and Not-Japan + Korea cohorts.
Conclusions: Good efficacy and an acceptable safety profile were observed for FF/VI 100/25 μg and 200/
25 μg OD in East Asian asthma patients; these globally recommended doses are appropriate for asthma
patients in Japan.
Trial registration: Clinicaltrials.gov registration numbers: NCT01165138, NCT01134042, NCT01086384,
NCT00603278, NCT00603382.
Keywords: β2-adrenergic receptor agonists, Asthma, Glucocorticoids, Japan, Treatment outcome
* Correspondence: annette.s.gross@gsk.com
1Clinical Pharmacology Modelling & Simulation, GSK R&D, 82 Hughes Ave,
Ermington, Sydney NSW 2115, Australia
Full list of author information is available at the end of the article
© 2015 Gross et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gross et al. BMC Pulmonary Medicine  (2015) 15:165 
DOI 10.1186/s12890-015-0159-z
Background
Asthma represents a considerable disease burden world-
wide. The prevalence of asthma in Japan is amongst the
highest in Asia [1]. Japanese [2] and global asthma guide-
lines [3] recommend the use of a low-dose inhaled
corticosteroid (ICS) and long-acting β2-agonist (LABA)
combination as step-up therapy for asthma patients
uncontrolled using reliever medication and low-dose ICS
alone. The inhaled ICS and LABA combination of flutica-
sone furoate (FF) and vilanterol (VI) is suitable for once-
daily (OD) dosing having 24 h efficacy in asthma patients
[4, 5]. FF/VI is delivered via the ELLIPTA® dry powder
inhaler (DPI; ELLIPTA® is a trademark of the GSK group
of companies).
The Japanese and global asthma guidelines support the
use of ICS/LABA combination inhalers [2, 3]; they reduce
the number of inhalation procedures, increase patient
adherence, and reduce the risk of the LABA being deliv-
ered alone [2]. Additionally, OD therapy has been shown
to improve treatment adherence in asthma patients [6, 7]
and is associated with treatment success and decreased
healthcare costs [8]. OD FF/VI 100/25 μg and 200/25 μg
are approved in Japan, the USA, and the European Union
for the treatment of asthma.
The multiregional global development program of FF/VI
included patients from a range of ethnic groups, including
East Asian patients from Japan and Korea. Based on the
totality of data from the global development program, the
100/25 μg and 200/25 μg strengths of FF/VI were recom-
mended for the treatment of asthma. As responses to
pharmacotherapy can vary across ethnic groups [9, 10], the
potential ethnic sensitivity of FF/VI efficacy and safety in
East Asian patients was assessed, using data from the stud-
ies that included asthma patients in Japan and Korea. This
analysis also supported the asthma FF/VI submission for
regulatory approval in Japan. Consequently, the focus of
this assessment is asthma patients in Japan and therefore,
efficacy data from patients in Japan have been compared
with data from patients in all countries other than Japan.
This comparison is important to determine whether the
results in the subjects in Japan are comparable with all
other subjects studied and, therefore, whether there is a
major difference in drug response in patients in Japan rela-
tive to all other subjects studied. To provide more reliable
conclusions on the safety profile of FF/VI in East Asian
asthma patients, safety data from patients in Korea were
included to increase the number of patients in the safety
assessment. The safety results of asthma patients from
Japan and/or Japan + Korea versus Not-Japan and/ or Not-
Japan + Korea have therefore been compared.
Methods
This was a pre-specified efficacy and safety subgroup
analysis of all multicenter, randomized, double-blind,
parallel-group, multiregional studies that included East
Asian asthma patients recruited in Japan (three Phase III
studies: efficacy assessment) and Japan and/or Korea
(five studies: safety assessment). Inclusion and exclusion
criteria are presented in each clinical trial summary
(Clinicaltrials.gov; registration numbers: NCT01165138,
NCT01134042, NCT01086384, NCT00603278 and
NCT00603382) and asthma-related clinical criteria are
described in Additional Files 1 and 2. In brief, non-
smoking patients with a diagnosis of asthma as defined
by the National Institutes of Health [11] aged ≥12 years
with a pre-bronchodilator % predicted forced expiratory
volume in one second (FEV1) of 40–90 %, and FEV1
reversibility of ≥12 % and ≥200 mL within 10–40 min
following 200–400 μg inhaled salbutamol were included.
Permitted baseline asthma therapies are described in
Additional Files 1 and 2. All studies included in the
analysis were approved by local ethics committees
(Additional File 3) and carried out in accordance with
the Declaration of Helsinki [12]. All patients provided
written informed consent prior to undertaking any
study-related procedures.
Efficacy analysis
Efficacy data are presented from three Phase III studies
that included asthma patients in Japan: HZA106827
(Clinicaltrials.gov registration number NCT01165138)
[4]; HZA106829 (NCT01134042) [5]; HZA106837
(NCT01086384) [13] (Additional File 1). FF/VI 100/
25 μg OD and FF 100 μg OD were investigated in stud-
ies HZA106827 (placebo-controlled) and HZA106837.
FF/VI 200/25 μg OD, FF 200 μg OD, and fluticasone
propionate (FP) 500 μg twice daily (BD) were investi-
gated in study HZA106829. FF/VI and placebo were de-
livered via the ELLIPTA DPI and FP was delivered via
the DISKUS® (DISKUS® is a trademark of the GSK group
of companies) DPI. A range of efficacy endpoints were
assessed in the individual studies, but only trough FEV1
measured at the end of a dosing interval (the primary
endpoint in studies HZA106827 and HZA106829 and a
secondary endpoint in study HZA106837) was analyzed
in the Japan subgroup, as pre-specified in the analysis
plan. Efficacy data were analyzed for patients recruited
from Japan (Japan cohort), all patients that were not re-
cruited from Japan (Not-Japan cohort), and all patients
studied (Overall population). Patients were assigned to
these cohorts according to the country in which they
were recruited and not according to race. Ease of use of
the ELLIPTA inhaler was also assessed by questionnaire
in study HZA106827.
Change from baseline in trough FEV1 at Week 12 was
pooled for each treatment arm from studies HZA106827
and HZA106837. Statistical analyses for treatment com-
parisons at Week 12 were conducted for FF/VI 100/25 μg
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versus placebo, FF/VI 100/25 μg versus FF 100 μg, and FF
100 μg versus placebo. In the individual studies included
in this analysis, sensitivity analyses (using repeated mea-
sures analyses) supported the primary analysis using last
observation carried forward (LOCF) data for imputation
of missing data. Consequently, LOCF data were used to
perform the current statistical analysis using an analysis of
covariance (ANCOVA) model. Effects due to geographic
region, baseline FEV1, gender, age, treatment group, and
study were modeled. An interaction term for treatment by
geographic region (Japan/Not-Japan) was also included in
the model. A similar modeling process was used to
analyze the results of the FP 500 μg BD-controlled study
HZA106829, in which FF/VI 200/25 μg and FF 200 μg
were assessed at Weeks 12 (post-hoc analysis) and 24,
using last observation carried forward data.
Withdrawals due to lack of efficacy were summarized
for each cohort in the efficacy dataset.
Safety analysis
Safety data were pooled from five clinical studies: the
three studies included in the efficacy assessment and an
additional two placebo-controlled FF Phase IIb studies
that included East Asian patients in Korea: FFA109685
(NCT00603278) [14]; FFA109687 (NCT00603382) [15]
(Additional File 2). These two studies were included in the
integrated safety analysis to increase the number of East
Asian patients assessed and thereby increase confidence
in the results. There are similarities in intrinsic and extrin-
sic ethnic factors in the populations of Japan and Korea
[16–18], supporting the pooling of patient results in these
two East Asian populations, which has increased the num-
ber of East Asian patients assessed and thereby increased
confidence in the conclusions that can be drawn.
All five studies assessed a comprehensive range of safety
endpoints, which are presented in the relevant publica-
tions; however, for brevity we only assessed key safety data
in the Japan subgroup, as pre-specified in the analysis plan.
Safety data were compared between treatment arms for
patients recruited from Japan and Korea (Japan + Korea
cohort), patients recruited from all other countries (Not-
Japan + Korea cohort), and all patients studied (Overall
population). The safety results are considered for OD
placebo, FF/VI 100/25 μg, FF/VI 200/25 μg, FF 100 μg,
and FF 200 μg from studies HZA106827, HZA106837,
HZA106829, FFA109685, and FFA109687. Results for the
doses of FF monotherapy that were not progressed to
Phase III for FF/VI from these five studies are not pre-
sented. FP 100 μg BD, FP 250 μg BD, and FP 500 μg BD
were also included in the analysis of urinary cortisol data.
The incidence of all adverse events (AEs), treatment-
related AEs, and serious AEs (SAEs), including exacer-
bations, was summarized for patients in Japan + Korea,
Not-Japan + Korea, and the Overall population of the
pooled data set. Electrocardiogram (ECG) results in-
cluding QT corrected using Frederica’s correction
(QTcF) were also assessed in a subset of patients from
HZA106827 and HZA106829. AEs related to known
ICS or LABA class effects were a focus, including lower
respiratory tract infections (bronchitis and pneumonia),
cardiovascular effects (heart rate and ECG), and effects
on glucose and potassium. An Asthma Composite
Endpoint was also derived to assess independently ad-
judicated asthma-related hospitalizations, intubations,
and deaths in studies HZA106837, HZA106827, and
HZA106829.
The urinary cortisol excretion over 24 h was measured
at baseline and at the end of the treatment period in a sub-
set of patients from studies FFA109685, FFA109687,
HZA106827, and HZA106829 (Urinary Cortisol popula-
tion). For treatment comparisons, the urinary cortisol
excretion ratio (end of treatment/baseline) was analyzed
using an ANCOVA model of the log-transformed urinary
cortisol excretion with effects due to geographic region,
log baseline urinary cortisol, gender, age, treatment group,
and study. For the analysis by geographic region and for
estimation of regional treatment differences, an interaction
term for treatment by geographic region (Japan + Korea/
Not-Japan + Korea) was also included in the model.
Withdrawals due to AEs were summarized for each
cohort in the safety dataset.
Results
Efficacy analysis
The intent-to-treat populations in the three efficacy studies
comprised 3,214 patients recruited in 11 countries (overall
population); including 148 patients (5 %) recruited from
Japan (Additional File 1). Eighty-five percent of patients in
the Overall population and 70 % of the Japan cohort com-
pleted the respective study. A higher proportion of patients
recruited from Japan (14 %; N = 21/148) than Not-Japan
(3 %; N = 104/3,066) withdrew due to lack of efficacy. In
the Japan cohort, a greater proportion of patients withdraw
due to lack of efficacy with placebo (42 %) than with FF/VI
(7–9 %). A similar pattern was observed in the Not-Japan
group (placebo 13 %, FF/VI 1–3 %).
Demographic and baseline characteristics for the
Japan and Not-Japan patients are presented in Table 1.
All patients recruited from Japan were of East Asian
ancestry and patients from the Not-Japan cohort were
principally White/Caucasian (81 %), but included
small proportions of patients of a range of geographic
ancestries (Additional File 1). Mean baseline pre-
bronchodilator FEV1 was lower in patients recruited
from Japan than Not-Japan, consistent with the litera-
ture and the lower average height of the Japan pa-
tients [19, 20]. Furthermore, patients recruited from
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Japan had greater mean % predicted FEV1 values than
the Not-Japan patients.
At Week 12, increases from baseline in trough FEV1
were observed for FF/VI 100/25 μg, FF/VI 200/25 μg, and
all active treatments in the Japan and Not-Japan patients
(Tables 2 and 3, and Fig. 1). The least-squares mean
change from baseline in the placebo group showed a slight
decrease in the Japan cohort (−0.022 L) compared with an
increase in the Not-Japan cohort (0.133 L). Consequently,
greater improvements from baseline for FF/VI 100/25 μg
OD versus placebo were observed in patients recruited
from Japan than Not-Japan, although the variability was
greater in the Japan population due to the smaller number
of subjects (Table 2). Adjusted treatment differences for
FF/VI 100/25 μg versus placebo, FF 100 μg versus placebo,
and FF/VI 100/25 μg versus FF 100 μg were directionally
the same in the Japan and Not-Japan populations (Table 2,
Additional File 4). Furthermore, there was no evidence of
a statistically significant difference in trough FEV1 treat-
ment effect between Japan and Not-Japan patients at
Week 12 (P = 0.403).
In the separate FP 500 μg BD-controlled study that
assessed FF/VI 200/25 μg and FF 200 μg at Weeks 12
and 24, the least-squares mean changes from baseline in
trough FEV1 in all treatment arms were consistent in the
Japan and Not-Japan patients (Table 3). The results in
the Japan subset should be interpreted with caution due
to the low number of patients in each treatment arm.
Nevertheless in the Japan patients, the least-squares
mean changes from baseline in trough FEV1 at Week 24
were numerically greater with OD FF/VI 200/25 μg
(0.355 L) than with OD FF 200 μg (0.086 L), or BD FP
500 μg (0.110 L). This pattern was consistent with the
results in the Not-Japan patients (FF/VI 200/25 μg:
0.396 L; FF 200 μg: 0.206 L; FP 500 μg: 0.191 L).
In the Japanese asthma patients, the ELLIPTA DPI
was considered easy or very easy to use by the majority
of subjects (77 %), which is consistent with results for
the Overall patient population (Additional Files 5 and 6).
Safety analysis
The safety analysis included 188 patients (5 %) re-
cruited from Japan and Korea (Japan N = 148, Korea
N = 40) included in the five studies (Overall Safety
population N = 4,028 recruited from 21 countries
(Additional Files 1 and 2). Demographic and baseline
characteristics of the Japan + Korea patients in the
Safety population (data not shown) were consistent with
the Efficacy population (Table 1). Studies were completed
by 139 (74 %) patients in the Japan + Korea cohort and
3,266 (85 %) patients in the Not-Japan + Korea cohort.
The number of patients who withdrew due to an AE








Age, years* 47.5 (14.66) 41.9 (16.63) 42.2 (16.59)
Range: min, max 20, 82 12, 84 12, 84
Male/female, % 38/62 36/64 36/64
Weight, kg* 62.5 (13.63) 76.2 (19.29) 75.5 (19.28)
Height, cm* 160.7 (8.05) 165.7 (9.98) 165.5 (9.96)
Screening and baseline lung function characteristics
Screening
Pre-bronchodilator FEV1, L* 1.87 (0.505) 2.13
† (0.619) 2.12‡(0.617)
% predicted pre-bronchodilator FEV1, %* 72.63 (10.715) 67.39
† (11.179) 67.63‡ (11.210)
Post-bronchodilator FEV1, L * 2.34 (0.638) 2.67
§ (0.768) 2.65¶ (0.766)
Absolute reversibility in FEV1, mL* 463.6 (258.51) 537.5
‖ (306.75) 534.1** (305.05)
Range: min,max 197.0, 2055.0 6.0, 2628.0 6.0, 2628.0
FEV1 reversibility, %* 25.3 (14.00) 26.1
‖ (14.95) 26.1** (14.90)
Range: min, max 12.0–129.9 0.3–125.2 0.3–129.9
Baseline
Baseline FEV1, L* 1.93
†† (0.548) 2.23‡‡ (0.647) 2.22§§ (0.646)
% predicted¶¶ FEV1 at baseline, %* 74.66
†† (11.127) 70.57‡‡ (11.182) 70.75§§ (11.210)
FEV1 forced expiratory volume in one second, min minimum, max maximum
Efficacy population consists of data from studies HZA106827, HZA106829, and HZA106837. *Mean (SD); †N = 3,055; ‡N = 3,203; §N = 3,063; ¶N = 3,211; ‖N = 3,052;
**N = 3,200; ††N = 147; ‡‡N = 3,059; §§N = 3,206; ¶¶Study HZA106837 used the prediction equation of Hankinson et al. 1999 [34]; studies HZA106827 and HZA106829
used Hankinson et al. 2010 [35]
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Table 2 Treatment differences for change from baseline in trough FEV1 (L) at Week 12 (Efficacy population)
Placebo FF/VI 100/25 μg OD FF 100 μg OD
Overall N 203 1,210 1,215
n† 193 1,201 1,203
LS mean change from baseline (SE) 0.120 (0.0333) 0.301 (0.0116) 0.225 (0.0116)
Difference vs placebo (95 % CI) – 0.181* (0.111–0.252) 0.105* (0.034–0.175)
Difference vs FF 100 μg (95 % CI) – 0.077* (0.045–0.108) –
Japan N 19 47 46
n† 18 46 46
LS mean change from baseline (SE) −0.022 (0.0955) 0.301 (0.0590) 0.194 (0.0591)
Difference vs placebo (95 % CI) – 0.323 (0.104–0.542) 0.216 (−0.003–0.436)
Difference vs FF 100 μg (95 % CI) – 0.107 (−0.056–0.270) –
Not-Japan N 184 1,163 1,169
n† 175 1,155 1,157
LS mean change from baseline (SE) 0.133 (0.0345) 0.301 (0.0118) 0.226 (0.0118)
Difference vs placebo (95 % CI) – 0.168 (0.095–0.241) 0.093 (0.020–0.166)
Difference vs FF 100 μg (95 % CI) – 0.075 (0.043–0.108) –
CI confidence interval, FF fluticasone furoate, LS least-squares, OD once daily, SE standard error, VI vilanterol
All values are in L. Data from studies HZA106827 and HZA106837. †Number of patients with analyzable data at Week 12; *P ≤ 0.003; Overall: FF/VI 100/25 μg vs
placebo, FF100 μg vs placebo, FF/VI 100/25 μg vs FF100 μg
Table 3 Treatment differences and change from baseline in trough FEV1 (HZA106829; Efficacy population)
FP 500 μg BD FF/VI 200/25 μg OD FF 200 μg OD
Week 12 Week 24 Week 12 Week 24 Week 12 Week 24
Overall N 195 195 197 197 194 194
n† 190 190 187 187 186 186
LS mean change from
baseline (SE)
0.178 (0.0291) 0.183 (0.0300) 0.364 (0.0293) 0.394 (0.0302) 0.209 (0.0294) 0.201 (0.0303)
Difference vs FP
500 μg BD (95 % CI)
– – 0.187 (0.106–0.268) 0.210* (0.127–0.294) 0.032 (−0.050–0.113) 0.018 (−0.066–0.102)
Difference vs FF 200 μg
OD (95 % CI)
– – 0.155 (0.074–0.237) 0.193* (0.108–0.277) – –
Japan‡ N 11 11 14 14 11 11
n† 10 10 13 13 11 11
LS mean change from
baseline (SE)
0.136(0.1271) 0.110(0.1310) 0.399 (0.1118) 0.355 (0.1152) 0.097 (0.1226) 0.086 (0.1263)
Not-
Japan
N 184 184 183 183 183 183
n† 180 180 174 174 175 175
LS mean change from
baseline (SE)
0.183 (0.0300) 0.191 (0.0309) 0.361 (0.0304) 0.396 (0.0313) 0.214 (0.0304) 0.206 (0.0314)
Difference vs FP 500 μg
BD (95 % CI)
– – 0.178 (0.094–0.262) 0.205 (0.119–0.291) 0.031 (−0.053–0.115) 0.015 (−0.072–0.101)
Difference vs FF 200 μg
OD (95 % CI)
– – 0.147 (0.062–0.231) 0.190 (0.103–0.277) – –
BD twice daily, CI confidence interval, FEV1 forced expiratory volume in one second, FF fluticasone furoate, FP fluticasone propionate, LS least-squares, OD once
daily, SE standard error, VI vilanterol
All values are in L. Analysis of covariance (ANCOVA) model using last observation carried forward. †Number of patients with analyzable data; ‡Differences vs FP
500 μg BD and FF 200 μg BD are not presented for the Japan group due the low number of patients in this analysis; *P ≤ 0.001
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with FF/VI 100/25 μg, FF/VI 200/25 μg, and placebo
in Japan + Korea was 3 (6 %), 1 (7 %), and 0 patients,
respectively, and for Not-Japan + Korea was 14 (1 %),
6 (3 %), and 1 (<1 %), respectively.
Exposure to treatment varied across treatment arms as
a consequence of the different durations of the studies
integrated (Additional File 7) and should be considered
when interpreting the incidence of AEs in each treat-
ment group. For example, in both Japan + Korea and
Not-Japan + Korea patients, there was a >5-fold longer
mean duration of exposure in the FF/VI 100/25 μg treat-
ment group relative to the placebo group.
On-treatment AEs (Table 4) were reported by a greater
proportion of Japan +Korea patients (placebo: 41 %; FF/VI:
64–79 %; FF: 69–73 %) than Not-Japan + Korea patients
(placebo: 23 %; FF/VI: 45–57 %; FF: 36–54 %). The most
frequently reported on-treatment AEs in all populations
were nasopharyngitis, headache, bronchitis, and upper
respiratory tract infections (Additional File 8). A greater
proportion of Japan +Korea patients reported nasopharyn-
gitis (placebo: 21 %; FF/VI: 49–50 %; FF: 23–29 %) than
Not-Japan +Korea patients (placebo: 5 %; FF/VI: 10–13 %;
FF: 8–10 %). A lower proportion of Japan + Korea pa-
tients reported headache (placebo: 3 %; FF/VI: 0–6 %;
FF: 7–9 %) than Not-Japan + Korea patients (placebo:
6 %; FF/VI: 6–17 %; FF: 7–15 %). For the pooled
dataset, the incidences of AEs deemed to be treatment
related by the investigator, as well as fatal SAEs and
non-fatal SAEs, were all low and generally reported for
similar proportions of patients recruited from Japan +
Korea and Not-Japan + Korea, with no trends across
active treatment arms (Table 4). The most commonly
reported treatment-related AEs in Japan + Korea were
the well described local ICS effects of candidiasis and
dysphonia, which were also among the most common
treatment-related AEs in the Not-Japan + Korea cohort.
For other potential class-related effects, the incidence
of AEs related to blood glucose or potassium was low
in the patients recruited from Japan + Korea and Not-
Japan + Korea. Changes in heart rate ≥6 bpm relative to
placebo were uncommon. Changes from baseline in the
maximum post-baseline QTcF were consistent across all
Fig. 1 Change from baseline in trough FEV1 at Week 12 (Efficacy population). Efficacy population consists of data from studies HZA106827, HZA106829,
and HZA106837. Number of patients analyzed in a) Overall population: N= 193 placebo, N= 1,201 FF/VI 100/25 μg OD, N= 187 FF/VI 200/25 μg OD,
N= 1,203 FF 100 μg OD, N= 186 FF 200 μg OD, N= 190 FP 500 μg BD; b) Japan cohort: N= 18 placebo, N= 46 FF/VI 100/25 μg OD, N= 13 FF/VI 200/
25 μg OD, N= 46 FF 100 μg OD, N= 11 FF 200 μg OD, N= 10 FP 500 μg BD; c) Not-Japan cohort: N= 175 placebo, N= 1,155 FF/VI 100/25 μg OD, N= 174
FF/VI 200/25 μg OD, N= 1,157 FF 100 μg OD, N= 175 FF 200 μg OD, N= 180 FP 500 μg BD. The limits of the box represent the interquartile range (IQR)
from the 25th to 75th percentiles, respectively, for the lower and upper limits of the box; error bars represent the minimum and maximum values within
1.5 × IQR below and above the 25th and 75th percentiles, respectively; the horizontal line within the box represents the median; + represents the mean;
symbols represent data that are either <1.5 × IQR below the 25th percentile or >1.5 × IQR above the 75th percentile. BD twice daily, FEV1 forced expiratory
volume in one second, FF fluticasone furoate, FP fluticasone propionate, OD once daily, VI vilanterol
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treatment arms, including placebo, in the Japan + Korea
and Not-Japan + Korea patients. The incidence of ECG
abnormalities of potential clinical importance did not
increase for any post-dose assessment relative to pre-dose
assessments for any treatment arm in any population.
There were two SAEs (both subarachnoid hemorrhage)
in Japan +Korea patients (FF/VI 100/25 μgN = 1; FF
100 μg N = 1), which were not considered treatment re-
lated. In the Overall population, the most frequent SAE
was asthma exacerbation (FF/VI 100/25 μgN = 11; FF
100 μgN = 9; FF 200 μgN = 1). For the Asthma Composite
Endpoint, no events (asthma-related hospitalizations, intu-
bations, and deaths) were reported for patients recruited
from Japan + Korea, and the incidence was <1 % in each
treatment arm in Not-Japan +Korea patients. The inci-
dence of respiratory-related SAEs and pneumonia-related
events was low in both the Japan +Korea and Not-Japan +
Korea cohorts.
The urinary cortisol population comprised 1,385 patients (88
[6 %] recruited from Japan+Korea). Geometric mean ratios of
24 h urinary cortisol excretion at the end of treatment relative
to baseline were generally close to one (Fig. 2). Treatment
comparisons for the Japan+Korea and Not-Japan+Korea
cohorts were performed for FF/VI 100/25 μg versus FF 100 μg,
FF/VI 200/25 μg versus FF 200 μg, and FF 100 μg or FF 200 μg
versus placebo, and were not statistically significant (the 95 %
confidence intervals encompassed one; Table 5). In the Overall
population, only FF 200 μg versus placebo was associated with
statistically lower cortisol ratios (16 % reduction in urine cortisol
excretion [ratio of end of treatment to baseline]), which is
unlikely to be clinically relevant (Table 5). No statistically signifi-
cant differences in the treatment comparisons were observed
between the Japan+Korea and the Not-Japan+Korea cohorts
(Additional File 9).
Discussion
The ethnic sensitivity of the novel OD treatment FF/VI in
East Asian asthma patients included in Phase IIb and
Phase III clinical studies has been assessed in this analysis.
The efficacy (trough FEV1) results in asthma patients in
Japan and the safety profile observed in asthma patients in
Table 4 Incidence of on-treatment AEs by treatment group and patient cohort (Safety population)
Incidence of AEs, n/N (%)
Placebo FF/VI 100/25 μg OD FF/VI 200/25 μg OD FF 100 μg OD FF 200 μg OD
Range of treatment duration of studies integrated (weeks) 8–12 12–76 24 8–76 8–24
On-treatment All AEs
Japan + Korea 12/29 (41) 37/47 (79)* 9/14 (64)* 38/55 (69) 16/22 (73)
Not-Japan + Korea 87/375 (23) 658/1,163 (57) 83/183 (45) 744/1,375 (54) 134/368 (36)
Overall 99/404 (25) 695/1,210 (57) 92/197 (47) 782/1,430 (55) 150/390 (38)
On-treatment Drug-Related AEs
Japan + Korea 0/29 (0) 4/47 (9)* 3/14 (21)* 1/55 (2) 2/22 (9)
Not-Japan + Korea 6/375 (2) 79/1,163 (7) 14/183 (8) 90/1,375 (7) 17/368 (5)
Overall 6/404 (1) 83/1,210 (7) 17/197 (9) 91/1,430 (6) 19/390 (5)
On-treatment AEs Leading to Permanent Discontinuation
of Investigative Product or Withdrawal from the Study
Japan + Korea 0/29 (0) 3/47 (6)* 1/14 (7)* 2/55 (4) 1/22 (5)
Not-Japan + Korea 1/375 (<1) 15/1,163 (1) 6/183 (3) 21/1,375 (2) 4/368 (1)
Overall 1/404 (<1) 18/1,210 (1) 7/197 (4) 23/1,430 (2) 5/390 (1)
On-treatment Non-fatal Serious AEs
Japan + Korea 0/29 (0) 1/47 (2)* 0/14 (0)* 1/55 (2) 0/22 (0)
Not-Japan + Korea 0/375 (0) 39/1,163 (3) 6/183 (3) 29/1,375 (2) 1/368 (<1)
Overall 0/404 (0) 40/1,210 (3) 6/197 (3) 30/1,430 (2) 1/390 (<1)
On-treatment Fatal AEs
Japan + Korea 0/29 (0) 0/47 (0)* 0/14 (0)* 0/55 (0) 0/22 (0)
Not-Japan + Korea 0/375 (0) 1/1,163 (<1) 0/183 (0) 1/1,375 (<1) 0/368 (0)
Overall 0/404 (0) 1/1,210†(<1) 0/197 (0) 1/1,430 (<1) 0/390 (0)
AE adverse event, FF fluticasone furoate, OD once daily, VI vilanterol
Safety population consists of data from studies HZA106827, HZA106829, HZA106837, FFA109685, and FFA109687. *Only patients recruited from Japan; †One
additional patient (South East Asian) died during follow-up (91 days after withdrawal)
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Japan + Korea did not indicate that a different clinical dose
of FF/VI is required in East Asian asthma patients, relative
to non-East Asian patients.
In both the Japan and Not-Japan cohorts, a notably
higher proportion of patients receiving placebo withdrew
due to lack of efficacy, relative to patients receiving FF/VI.
The improvements in trough FEV1 at Week 12 show that
asthma patients in Japan benefited from FF/VI 100/25 μg
or FF/VI 200/25 μg, and that response to treatment in
Japanese patients is similar to that seen in the global
population, suggesting the doses used in the global popu-
lation are appropriate for use in Japanese patients. Patients
recruited from Japan had a lower placebo response than
patients from Not-Japan, resulting in the observation of
greater numerical improvements with FF/VI versus pla-
cebo in the Japan cohort. For the FF/VI 100/25 μg versus
FF 100 μg treatment comparison, differences between
populations were less pronounced. The results for FF/VI
200/25 μg OD versus FP 500 μg BD at Week 12 and Week
24 also demonstrate that the change from baseline data
for trough FEV1 appeared to be similar between the Japan
and Not-Japan asthma patients.
There was a trend towards a greater proportion of
patients in Japan + Korea reporting on-treatment AEs
with FF/VI or FF than in the Not-Japan + Korea co-
hort. This trend was also observed with placebo,
which indicates that patients in Japan + Korea had a
higher tendency to report AEs in general. Regional
differences in AE reporting have been observed for
other drugs [21]. Furthermore, there was no evidence
of ethnic differences for treatment-related AEs or
class-related AEs. There were no deaths or treatment-
related SAEs in patients recruited from Japan + Korea.
The slightly greater proportion of withdrawals due to
AEs in the Japan + Korea versus Not-Japan + Korea
patients should be interpreted with caution due to
low patient numbers; generally, withdrawals due to AEs
were low and there was no clear indication of an ethnic
difference. The safety profile of FF/VI in this analysis is
consistent with that reported previously for Japanese
asthma patients from a 12-month safety study of FF/VI
[22], as well as in non-Japanese asthma patients in other
multiregional studies [23, 24].
Systemic exposure to high-dose ICS has been associ-
ated with unwanted changes in hypothalamic–pituitary–
adrenal (HPA) axis function and cortisol suppression
[25]. Previous studies in Japanese subjects [26, 27] and
other multiregional studies [25, 28] have assessed the
Fig. 2 24h urinary cortisol excretion at the end of treatment relative to baseline (Urinary Cortisol population). Urinary cortisol population consists
of data from studies HZA106827, HZA106829, FFA109685, and FFA109687. Number of patients analyzed in a) Overall population: N = 258 placebo,
N = 153 FF/VI 100/25 μg OD, N = 140 FF/VI 200/25 μg OD, N = 301 FF 100 μg OD, N = 270 FF 200 μg OD, N = 70 FP 100 μg BD, N = 70 FP 250 μg
BD, N = 123 500 μg BD; b) Japan/Korea cohort: N = 14 placebo, N = 12* FF/VI 100/25 μg OD, N = 10* FF/VI 200/25 μg OD, N = 21 FF 100 μg OD, N
= 14 FF 200 μg OD, N = 2 FP 100 μg BD, N = 7 FP 250 μg BD, N = 8* FP 500 μg BD; c) Not-Japan/Korea cohort: N = 244 placebo, N = 141 FF/VI
100/25 μg OD, N = 130 FF/VI 200/25 μg OD, N = 280 FF 100 μg OD, N = 256 FF 200 μg OD, N = 68 FP 100 μg BD, N = 63 FP 250 μg BD, N = 115 FP
500 μg OD. See Fig. 1 for details of parameters represented by the box plot. *Patients from Japan only. BD twice daily, FP fluticasone propionate,
OD once daily, FF fluticasone furoate, VI vilanterol
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dose-dependent effect of inhaled FF (doses up to
4,000 μg administered as a single dose, including 800 μg
OD in Japanese) on urine or plasma cortisol. In the
current pooled analysis for the treatment comparison of
urine cortisol effect (FF versus placebo, or FF/VI versus
dose-matched FF), no statistically significant differences
were observed between the Japan + Korea and the Not-
Japan + Korea populations. In the Overall population of
the current pooled safety analysis, the FF 200 μg treat-
ment arm demonstrated a 16 % reduction in urine corti-
sol excretion (ratio of end of treatment to baseline)
relative to placebo, which was statistically significant but
unlikely to be clinically relevant. However, modeling of
the plasma FF concentration effect on urine or serum
cortisol in multinational populations [25] and in healthy
Japanese subjects [26] has demonstrated that clinical
doses of FF (≤200 μg) have not been associated with de-
creases in cortisol of clinical concern. In addition, the
definitive study of the effect of FF/VI 100/25 μg and
200/25 μg on the HPA axis, in which 24-h serum corti-
sol was assessed in patients with asthma, did not show a
significant reduction of cortisol levels relative to placebo
with either strength of FF/VI [28].
The absence of treatment-related changes of concern
in blood glucose or potassium concentrations for VI ad-
ministered as FF/VI are consistent with previous reports
[26, 29, 30] in healthy Western and Japanese subjects. In
the current analysis, there was no indication that VI ad-
ministered as FF/VI was related to ECG abnormalities,
consistent with previous reports in healthy Japanese sub-
jects [26] and a multiregional study [29], suggesting that
the clinical dose of VI 25 μg does not have a clinically
relevant impact on QT/QTc interval. Increases in heart
rate are a known LABA effect [31] and the small in-
creases from baseline in heart rate observed in the
current analysis are consistent with the small, transient
effects reported in other clinical studies with inhaled VI
[23, 32].
The pharmacokinetics of FF and VI have been charac-
terized during the FF/VI development program in
healthy subjects, including East Asians [26], as well as in
patients with asthma or COPD [33]. In healthy subjects,
higher FF systemic exposure (<2-fold) following oral in-
halation has been observed in East Asians than
Caucasians [27], which may be related to differences in
absorption from the lung [27]. However, as previously
Table 5 Treatment comparison of 24 h urinary cortisol excretion at end of treatment (nmol/24 h) (Urinary Cortisol population)
Placebo FF/VI 100/25 μg OD FF/VI 200/25 μg OD FF 100 μg OD FF 200 μg OD
Overall N 258 153 140 301 270
n† 258 153 140 301 270
LS geometric mean 64.29 56.01 56.90 61.43 54.10
LS ratio to baseline 1.03 0.9 0.91 0.99 0.87
Ratio to placebo (95 % CI) — — — 0.96 (0.85–1.08) 0.84 (0.71–0.99)*
Ratio to FF 100 μg (95 % CI) — 0.91 (0.78–1.06) — — —
Ratio to FF 200 μg (95 % CI) — — 1.05 (0.88–1.26) — —
Japan + Korea N 14 12 10 21 14
n† 14 12 10 21 14
LS geometric mean 71.40 68.27 47.52 66.13 49.20
LS ratio to baseline 1.15 1.10 0.76 1.06 0.79
Ratio to placebo (95 % CI) – – – 0.93 (0.56–1.52) 0.69 (0.40–1.20)
Ratio to FF 100 μg (95 % CI) – 1.03 (0.61–1.74) – – –
Ratio to FF 200 μg (95 % CI) – – 0.97 (0.53–1.78) – –
Not-Japan + Korea N 244 141 130 280 256
n† 244 141 130 280 256
LS geometric mean 63.73 55.11 58.00 61.09 54.34
LS ratio to baseline 1.02 0.89 0.93 0.98 0.87
Ratio to placebo (95 % CI) – – – 0.96 (0.84–1.09) 0.85 (0.72–1.01)
Ratio to FF 100 μg (95 % CI) – 0.90 (0.77–1.06) – – –
Ratio to FF 200 μg (95 % CI) – – 1.07 (0.89–1.28) – –
CI confidence interval, FF fluticasone furoate, LS least-squares, OD once daily, VI vilanterol
Data from studies FFA109685, FFA109687, HZA106827, and HZA106829. Analysis performed using ANCOVA with covariates of study, gender, age, treatment
group, geographical region, geographical region-by-treatment interaction (Japan + Korea and Not-Japan + Korea analysis only), and the log of baseline values.
†Number of patients with analyzable data at end of treatment; *P = 0.038; Overall FF 200 μg vs placebo
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described, clinical doses of FF (≤200 μg) have not been as-
sociated with urine cortisol suppression of clinical concern
in Japanese healthy subjects and asthma patients. Therefore,
the modest increase in FF systemic exposure anticipated in
East Asian asthma patients does not result in clinically sig-
nificant effects on HPA axis function. As previously noted,
effects potentially associated with systemic VI concentra-
tions (effects on glucose, potassium, and cardiovascular ef-
fects) were limited and were not of clinical concern in
Japan +Korea and Not-Japan +Korea patients with asthma.
The current analysis has some limitations. Only a lim-
ited total number of patients in Japan and Korea were
included in these multiregional clinical studies and the
Japan and Japan + Korea cohorts were not formally pow-
ered for statistical analysis. Furthermore, even though
these were pre-specified, a number of subgroup analyses
were performed and multiplicity issues should be con-
sidered when drawing inference from the results of these
analyses. It is also important to consider the differences
in duration of exposure to study drug across the five
studies, in particular, the markedly lower number of
patient-years of exposure to placebo that limits the abil-
ity to directly compare safety data. In addition, differ-
ences in study design restrict the treatment arms that
could be pooled for statistical comparisons of efficacy
data, preventing the statistical comparison of FF/VI 200/
25 μg versus placebo.
Conclusion
The totality of the data from the current analysis, taken
together with previously published results in Japanese
asthma patients and Japanese healthy subjects [22, 26, 27],
provide confidence that the efficacy and safety of FF/VI is
of low ethnic sensitivity and this supports the conclusion
that the same clinical doses of FF/VI (100/25 μg OD and
200/25 μg OD) are appropriate for both East Asian and
non-East Asian asthma patients.
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